From: Måns Rosén [Rosen@sbu.se]

Sent: 28 March 2008 08:18 **To:** NARHI Ulla (ENTR)

Subject: SV: Public consultation: The legal proposal on information to patients

Dear Ulla Narhi,

Our message below is our contribution to the consultation.

Best regards,

Måns Rosén

Från: Ulla.NARHI@ec.europa.eu [mailto:Ulla.NARHI@ec.europa.eu]

Skickat: den 22 februari 2008 09:33

Till: Måns Rosén

Ämne: RE: Public consultation: The legal proposal on information to patients

Dear Professor Rosen thank you for your message.

The Commission has the position that health professionals should be the primary source of health information. Other important sources are drug regulatory authorities, including other related organisations. This shall not be changed. In the key ideas of the legal proposal on information to patients we are introducing one source more, i.e. pharmaceutical companies who have the basic information about their products. This shall not replace the other sources.

The monitoring system in each Member States should assure the content of the information.

May I kindly ask you are you going to give a larger response to the public consultation? Is this message just your comment or your contribution to consultation?

If you need more information, please do not hesitate to contact me.

With best regards Ulla Narhi

From: Måns Rosén [mailto:Rosen@sbu.se] **Sent:** Friday, February 22, 2008 7:57 AM

To: NARHI Ulla (ENTR)

Subject: Public consultation: The legal proposal on information to patients

Public consultation: The Legal proposal on information to patients

On behalf of the Swedish Council on Technology Assessment in Health Care, we would like to make the following comments:

We do not believe this proposal is in line with the main policy objectives formulated in the paper. If pharmaceutical industry disseminate information, irrespective in which form, it should be considered as a plea by one party who has economic incentives to present information in favour of the product. It is still merely advertisement. Patients would benefit more if information is presented by medicines agencies or public HTAs (Health Technology Assessments) organisations.

Best regards

Måns Rosén Executive Director, professor rosen@sbu.se

Direct: +46-8-412 32 24 Exchange: +46-8-412 32 00

SBU - Swedish Council on Technology Assessment in Health Care Tyrgatan 7 SE - 114 86 Stockholm

http://www.sbu.se